Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib plus topical corticosteroids for moderate-to-severe atopic dermatitis after cyclosporine failure or intolerance
NL-OMON55793Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients achieving Investigator's Global Assessment 0 or 1 with at least 2-point improvement at Week 16. Started Jul 2018; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON55793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55793.